INTRODUCTION: Plasmapheresis is one of the methods of extracorporeal blood purification involving the removal of inflammatory mediators and antibodies. The procedure is used in a variety of conditions, including autoimmune diseases. The aim of the present study was to analyse the incidence of plasmapheresis-related complications in patients treated in the intensive care unit (ICU). METHODS: The analysis involved 370 plasmapheresis procedures in 54 patients. The data were collected from patients' medical records, including procedure protocols. RESULTS: The most common diseases treated with plasmapheresis included: myasthenia gravis (33.3%), Guillain-Barre syndrome (14%), Lyell's syndrome (9.3%), systemic lupus erythematosus (7.4%), and thrombotic thromcytopenic purpura (7.4%). The adverse side effects observed most frequently during plasma filtration were: fall in arterial blood pressure (8.4% of all procedures), arrhythmias (3.5%), sensations of cold with temporarily elevated temperature and paresthesias (1.1%, each). In most cases the symptoms were mild and transient. Severe and life-threatening episodes, i.e. shock, fall in arterial blood pressure requiring pressor amines, persistent arrhythmias and haemolysis, developed in 2.16% of procedures. CONCLUSIONS: Plasmapheresis can be considered a relatively safe method of treatment of ICU patients. Continuous observation and proper monitoring of patients provided by highly trained medical personnel are essential for its safety.
INTRODUCTION: Plasmapheresis is one of the methods of extracorporeal blood purification involving the removal of inflammatory mediators and antibodies. The procedure is used in a variety of conditions, including autoimmune diseases. The aim of the present study was to analyse the incidence of plasmapheresis-related complications in patients treated in the intensive care unit (ICU). METHODS: The analysis involved 370 plasmapheresis procedures in 54 patients. The data were collected from patients' medical records, including procedure protocols. RESULTS: The most common diseases treated with plasmapheresis included: myasthenia gravis (33.3%), Guillain-Barre syndrome (14%), Lyell's syndrome (9.3%), systemic lupus erythematosus (7.4%), and thrombotic thromcytopenic purpura (7.4%). The adverse side effects observed most frequently during plasma filtration were: fall in arterial blood pressure (8.4% of all procedures), arrhythmias (3.5%), sensations of cold with temporarily elevated temperature and paresthesias (1.1%, each). In most cases the symptoms were mild and transient. Severe and life-threatening episodes, i.e. shock, fall in arterial blood pressure requiring pressor amines, persistent arrhythmias and haemolysis, developed in 2.16% of procedures. CONCLUSIONS: Plasmapheresis can be considered a relatively safe method of treatment of ICU patients. Continuous observation and proper monitoring of patients provided by highly trained medical personnel are essential for its safety.
Authors: Jon A Kenniston; Brandy M Taylor; Gregory P Conley; Janja Cosic; Kris J Kopacz; Allison P Lindberg; Stephen R Comeau; Kateri Atkins; Jameson Bullen; Christopher TenHoor; Burt A Adelman; Daniel J Sexton; Thomas E Edwards; Andrew E Nixon Journal: J Biol Chem Date: 2017-09-06 Impact factor: 5.157
Authors: Gopal K Patidar; Kevin J Land; Hans Vrielink; Naomi Rahimi-Levene; Eldad J Dann; Hind Al-Humaidan; Steven L Spitalnik; Yashaswi Dhiman; Cynthia So-Osman; Salwa I Hindawi Journal: Vox Sang Date: 2021-03-17 Impact factor: 2.996
Authors: Santiago Bernal-Macías; Benjamín Reyes-Beltrán; Nicolás Molano-González; Daniel Augusto Vega; Claudia Bichernall; Luis Aurelio Díaz; Adriana Rojas-Villarraga; Juan-Manuel Anaya Journal: Lupus Sci Med Date: 2015-12-01
Authors: Seena Tabibi; Tara Tabibi; Rosalynn R Z Conic; Nassim Banisaeed; Michael B Streiff Journal: J Intensive Care Med Date: 2020-07-15 Impact factor: 3.510
Authors: Vera Bril; Michael Benatar; Henning Andersen; John Vissing; Melissa Brock; Bernhard Greve; Peter Kiessling; Franz Woltering; Laura Griffin; Peter Van den Bergh Journal: Neurology Date: 2020-11-20 Impact factor: 9.910
Authors: Patrick M Honore; Leonel Barreto Gutierrez; Luc Kugener; Sebastien Redant; Rachid Attou; Andrea Gallerani; David De Bels Journal: Crit Care Date: 2020-09-07 Impact factor: 9.097